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1. Introduction 
A tumor-related protein, squamous cell carcinoma antigen (SCCA) was first discovered in 
uterine cervical squamous cell carcinoma [1], and subsequently has been used as a useful 
tumor marker for squamous cell carcinoma of various organs [2-4]. Cloning and 
characterization of SCCA cDNA has revealed that SCCA belongs to serine proteinase 
inhibitor (serpin) family [5]. Since SCCA is present not only in squamous cell carcinomas but 
also in normal squamous epithelium, the biological function of SCCA is of great interest. 
The present paper reviews the current understanding of SCCA, focusing on its biological 
function in uterine cervical squamous cell carcinoma. 
2. Characteristics of SCCA 
SCCA consists of more than 10 protein fractions with different isoelectric points, ranging 
from 5.9 to 6.6, which are roughly divided into two groups: the acidic SCCAs with pIs of 
less than 6.25 and the neutral SCCAs with pIs of 6.25 or higher [6]. The neutral SCCAs are 
generally present inside the cell, whereas the acidic SCCAs are often increased in squamous 
cell carcinomas and is easily secreted by the cell [6]. In 1991, our laboratory reported the 
cloning of SCCA cDNA, which consist of 1,170 nucleotides coding for 390 amino acids [5]. 
Schneider et al. also found two SCCA genes (SCCA1 and SCCA2) and these two genes were 
tandemly arrayed at the human chromosome 18q21.3 locus [7, 8]. The predicted amino acid 
sequences of SCCA1 and SCCA2 are 92% identical and have identical predicted secondary 
structures, which suggests that SCCA1 gene encodes the neutral SCCA, while SCCA2 gene 
encodes the acidic SCCA [7]. SCCA1 inhibits the activities of serine proteinases, e.g. 
chymotrypsin and cysteine proteinases, e.g. cathepsin K, L, S and papain, whereas SCCA2 
inhibits serine proteinases such as cathepsin G and chymase in vitro [9-12] (Table 1). For 
these reasons, SCCA1 and SCCA2 are thought to have different biological functions. It is 
thus of interest to better understand the biological behaviors of SCCAs in normal squamous 
epithelium and squamous cell carcinomas.  
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Table 1. Inhibitory effects of SCCAs on proteinases. 
3. Evaluation of SCCA in clinical practice  
Serum SCCA levels have been used as an indicator of a variety of squamous cell carcinomas, 
including skin cancers, head and neck cancers, esophageal cancers, lung cancers, bladder 
cancers, epidermoid cancers of the anal canal, and malignant transformation of mature cystic 
ovarian teratoma [13]. Serum SCCA levels are especially useful for monitoring treatment 
efficacy, disease progression and recurrence. In general, increased serum SCCA levels reflect 
disease progression and poor prognosis in squamous cell carcinomas [13]. In advanced 
cancers, pretreatment serum SCCA levels are associated with clinical stages, tumor sizes, and 
lymph node involvement. Furthermore, over 6 ng/ml of serum SCCA level shows a significant 
independent effect on survival and disease-free survival [14]. Even in the early stage of uterine 
squamous cell carcinomas, elevated serum SCCA levels predict pelvic lymph node 
involvement and are associated with a poor prognosis [15]. Recently, patients with elevated 
SCCA2/SCCA1 mRNA ratios in uterine squamous cell carcinoma tissues were found to be at 
higher risk for recurrence in early stage uterine cervical cancers, suggesting SCCA2 is 
increased during cervical carcinogenesis [16]. In addition to malignant diseases, several benign 
and chronic inflammatory skin diseases, such as psoriasis, pemphigus, or eczema are often 
characterized by elevated SCCA levels [13]. SCCA will be a useful marker for monitoring the 
status of these diseases not only for malignant diseases but also for non-malignant diseases. 
4. Role of SCCA in normal squamous epithelial cells 
Human squamous epithelium is composed of four compartments; stratum germinativus, 
stratum spinosum, stratum granulosum and stratum corneum. Immunohistochemical staining 
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shows that SCCA is present in the spinous and granular compartments, but not in the basal 
and parabasal cells [17] (Fig. 1). SCCA is not present in the epithelial region adjacent to the 
squamo-columnar junction of the uterine cervix. Interestingly, SCCA levels begin to increase 
at 18-20 weeks of pregnancy for the first time when the fetal epidermis begins to cornify 
during the development of human fetal skins [18]. SCCA genes has been found in most of 
the eutheria (placental mammals), but not in other vertebrates [19]. Furthermore, several 
eutherian species show heterogeneous patterns of SCCA nucleotides in Southern blot 
analyses [19]. This suggests that SCCA has had a role in the stratification and differentiation 
of integuments during evolutional change.  
 
Fig. 1. Immunohistochemistry for SCCA expression in normal cervical squamous 
epithelium. SCCA is expressed in all epithelial layers except the basal layer (original 
magnification: X 100).  
The stratification and cornification of normal squamous epithelial cells are influenced by 
extracellular calcium concentrations. Calcium concentrations are low in the parabasal layer 
but high in the granular layers. Keratinocytes begin to stratify and cornify in the presence of 
high concentrations of calcium [20]. High concentrations of calcium stimulate the 
production of neutral SCCA, whereas low concentration of calcium stimulate the production 
of acidic SCCA [21].  
The final stage of differentiation of squamous epithelial cells is modulated by several 
cysteine proteinases, such as cathepsin L, calpain, and epidermal transglutaminase [20]. 
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SCCA1 inhibits cathepsin L and some of the proteinases in the spinous and granular layers, 
suggesting that SCCA1 inhibits UV-induced apoptosis of squamous epithelial cells to 
maintain barrier functions in the squamous epithelium. On the other hand, SCCA2 may act 
outside of the cells to enhance the cell adhesion system in the parabasal layer [22, 23], 
suggesting that SCCA2 may play important roles to maintain the structure of the normal 
squamous epithelium, particularly structure of the thick stratum corneum in mammalian 
species. 
5. Role of SCCA in squamous cell carcinoma of uterine cervix 
Anti-tumor therapeutics inhibits the cancer cell proliferation and induce necrotic and 
apoptotic cell death. However, some cancer cells acquire the ability to resist anti-tumor 
therapeutics. Thus, proliferation, cell invasion and migration are the most crucial biological 
events in the progression of cancer.  
Recently, much attention has been focused on the role of proteinases and their inhibitors in 
the malignant behavior of cancer cells. Proteinase inhibitors are thought to suppress the 
apoptotic process of cancer cells. Apoptosis involves complicated mechanisms with 
multistep pathways. Some serpins are involved in the apoptotic process. In squamous cell 
carcinoma tissues, the expression levels of SCCA2 are higher than those in normal 
squamous epithelial tissues, suggesting that SCCA2 plays a role in suppressing apoptotic 
cell death [24, 25]. Both SCCA1 and SCCA2 belong to the ov-serpin family, and some of the 
ov-serpins have been reported to inhibit apoptosis [5]. In fact, SCCA1 inhibits both serine 
proteinases and cysteine proteinases, and SCCA2 inhibits serine proteinases [9-12]. 
Although the target proteinases are different, both SCCA1 and SCCA2 inhibit apoptosis. 
SCCA1 suppresses apoptosis induced by activated natural killer cells, TNF-, irradiation 
and anti-tumor agents, while SCCA2 suppresses apoptosis induced by irradiation and TNF-
 [26-28]. Both SCCAs suppress the activity of caspase-3 and caspase-9 via down-regulation 
of p38 MAPK and/or MKK3/MKK6 [27]. These results suggest that SCCAs in tumor cells 
help to protect cancer cells from apoptotic cell death, both from therapeutic modalities and 
the immune systems. Proteinase inhibitors are also thought to suppress the invasion and 
metastasis of cancer cells by inhibiting proteinase activities that disrupt the cell-to-cell 
adhesion system. In the first step of cancer metastasis, loss of E-cadherin expression causes 
detachment of cancer cells from the primary tumor lesion. After the detachment from the 
primary tumor, cancer cells migrate, attach to vessels, and move to other organs through 
blood and lymph fluid flow. In fact, suppression of SCCA2 expression promoted cell 
invasion and cell migration with the decreased expression of E-cadherin [29, 30].Blockage of 
E-cadherin action suppressed SCCA production in squamous cell carcinoma cell lines [31]. 
Our immunohistochemical study on cervical squamous cell carcinoma revealed that SCCA2 
expression was significantly related with E-cadherin expression and that mixed pattern with 
loss and positive stained of SCCA2 and E-cadherin in primary lesions was strongly 
associated with high incidence of lymph node metastasis [32]. These facts strongly suggest 
that cancer cells with loss of SCCA2 expression, as well as loss of E-cadherin expression, 
metastasize to other organs including the lymph nodes. In contrast, increased expression of 
E-cadherin induces the increase of SCCA2 expression through a PI3K - Akt pathway in 
uterine squamous cell carcinoma cells [33]. These results suggest that the decrease in E-
cadherin expression causes cancer cells to detach from the primary tumor, and acquire the 
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activated E-cadherin – SCCA system, which leads to their aggregation, survival, and growth 
into metastatic tumors (Fig. 2).  
 
Fig. 2. Possible roles of SCCA in tumor cell survival and metastasis in uterine cervical 
squamous cell carcinoma. Cancer cells with abnormally high expression of SCCA are 
resistant to apoptosis induced by the immune system and therapeutic modalities. In 
contrast, cancer cells with abnormally low expression of SCCA show loss of E-cadherin 
expression, resulting in detachment from the primary tumor lesion. These cells migrate, 
attach to the vessels, and metastasize in other organs through blood and lymph fluid flow.  
6. Conclusions 
SCCAs have been regarded as a useful tumor marker for squamous cell carcinoma in clinical 
practice. Furthermore, they have some interesting biological functions. SCCAs are regarded 
as a useful tumor marker for squamous cell carcinoma in clinical practice. In normal 
squamous epithelium, SCCA may have roles in the stratification, cornification, barrier 
functions and structure of the epithelium. In squamous cell carcinomas, both SCCA1 and 
SCCA2 suppress apoptosis by inhibiting serine and cysteine proteinases concerned that 
function in the apoptotic pathway, resulting in the proliferation of cancer cells. Furthermore, 
suppression of SCCA2 promoted cancer cell invasion and migration with the decreased 
expression of E-cadherin, resulting in cancer cell metastases. Thus, SCCA appears to have 
roles not only in the normal squamous epithelium but also in the squamous cell carcinomas. 
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